πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 2,432 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12263156

Use of small molecule inhibitors of the BfrB:Bfd interaction in biofilms

The Board of Regents for Oklahoma State University Β· Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12264167

Fused tricyclic ring derivatives as SRC homology-2 phosphate inhibitors

NIKANG THERAPEUTICS, INC. Β· Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12263165

Small molecule inhibitors of cancer stem cells and mesenchymal cancer types

The Board of Regents of the University of Texas System Β· Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12251387

Substituted quinoxalines and benzo[c][1,2,5]oxadiazoles as DNA-PK inhibitors

Vertex Pharmaceuticals Incorporated Β· Granted Tue Mar 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12252493

Imidazo[1,2-c]pyrimidine derivatives as PRC2 inhibitors for treating cancer

Mirati Therapeutics, Inc. Β· Granted Tue Mar 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12252497

Ras inhibitors

Revolution Medicines, Inc. Β· Granted Tue Mar 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12251370

Small molecule inhibitors of the BfrB:Bfd interaction

The Board of Regents for Oklahoma State University Β· Granted Tue Mar 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12234460

Methods of treating decreased bone mineral density with cluster of differentiation 109 (CD

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Feb 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12233051

Treating primary or idiopathic hyperoxaluria with small molecule inhibitors of lactate deh

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Feb 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12227508

TGF-Ξ² inhibitors

Rigel Pharmaceuticals, Inc. Β· Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12226425

Inhibitors of ARG1 and/or ARG2

Arcus Biosciences, Inc. Β· Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12220415

WEE1 kinase inhibitors and methods of treating cancer using the same

The Regents of the University of Colorado, a Body Corporate Β· Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12221441

Plasma kallikrein inhibitors and uses thereof

Takeda Pharmaceutical Company Limited Β· Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12220421

Inhibitors of C. difficile spore germination

THE BOARDS OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS Β· Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12221491

PSMD9 inhibitors for the treatment of hepatic lipid dysregulation

The Regents of the University of California Β· Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12213973

Bacterial nitric oxide synthase inhibitors

Northwestern University Β· Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12215322

Treatment of liver disease with mitochondrial glycerol-3-phosphate acyltransferase (GPAM)

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12219327

Substituted isoindolines as PI3K-alpha inhibitors

Relay Therapeutics, Inc. Β· Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12209085

RET inhibitors, pharmaceutical compositions and uses thereof

SUNSHINE LAKE PHARMA CO., LTD. Β· Granted Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12202845

Ras inhibitors

Revolution Medicines, Inc. Β· Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12201617

HDAC6 inhibitors for treatment of metabolic disease and HFpEF

Tenaya Therapeutics, Inc. Β· Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12186324

Imidazopiperazine inhibitors of transcription activating proteins

The Board of Regents of the University of Texas System Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12187694

SLC26A3 inhibitors and use thereof

The Regents of the University of California Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12187731

Compounds useful as inhibitors of ATR kinase

Vertex Pharmaceuticals Incorporated Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted